BioNTech

BioNTech的“双面剧本”：一周涨24%背后，市场在赌什么？

Brett Shapiro -

BioNTech’s Momentum Trade: Riding a Rival’s Coattails Into Overbought Territory

BioNTech的“过山车”一周：从行业狂欢到技术性回调，肿瘤数据才是真正的胜负手

angelina -

BioNTech’s Seoul Test: A Pause in the Rally That Rode a Rival’s Coattails

angelina -

BioNTech的“被动狂欢”：一场由竞争对手点燃的行情，能走多远？

Brett Shapiro -

BioNTech的“交接棒”时刻：股价横盘背后，华尔街多空分歧与百亿现金的缓冲垫

angelina -

BioNTech的“换帅时刻”：肿瘤数据密集出炉，百亿现金能否托底转型？

angelina -

BioNTech的转型赌局：现金流充裕但营收滑坡，新帅上任前能否守住估值底线？

angelina -

BioNTech下调2026年营收指引 肿瘤管线与帅印交接成市场关注焦点

Brett Shapiro -

BioNTech’s €16.6 Billion Cushion Buys Time — But Not Certainty — as Founder Era Winds Down

kashif hafeez -

BioNTech的“双线作战”：肿瘤管线冲刺与新冠业务萎缩的赛跑

angelina -

BioNTech权力交接倒计时：新帅尚未上任，三场关键试验已定成败

Brett Shapiro -

BioNTech的“瘦身”与“输血”：新帅上任前，一场千亿市值的保卫战

BioNTech的转型十字路口：业绩承压与帅印交接并行，肿瘤管线成胜负手

BioNTech的转型阵痛期：业绩滑坡、帅印交接与百亿现金储备的三重奏

angelina -
123...15Page 2 of 15